The GLP 1 Revolution
Semaglutide is a long acting GLP 1 receptor agonist that has fundamentally changed the landscape of metabolic research. Developed as an analogue of human GLP 1, Semaglutide incorporates strategic amino acid modifications and a fatty acid chain that extend its half life to approximately 7 days, enabling once weekly dosing.
Molecular Design
The molecular design of Semaglutide represents elegant pharmaceutical engineering. Key modifications include substitution at position 8 (Aib for Ala) to resist DPP 4 degradation, substitution at position 34 (Arg for Lys) to prevent fatty acid binding at this site, and attachment of a C18 fatty diacid at position 26 via a linker to enable albumin binding and extend half life.
STEP Clinical Programme
The STEP (Semaglutide Treatment Effect in People with obesity) trials established the evidence base for Semaglutide in weight management research:
STEP 1: 2.4mg weekly Semaglutide achieved approximately 14.9% weight loss versus 2.4% with placebo at 68 weeks.
STEP 2: In participants with type 2 diabetes, 2.4mg achieved approximately 9.6% weight loss.
STEP 3: Combined with intensive behavioural therapy, approximately 16% weight loss was achieved.
STEP 4: Demonstrated significant weight regain upon discontinuation, highlighting the importance of sustained treatment.
Cardiovascular Research
The SELECT trial provided groundbreaking cardiovascular data, demonstrating a 20% reduction in major adverse cardiovascular events (MACE) in participants with established cardiovascular disease but without diabetes. This was the first time a weight management compound demonstrated direct cardiovascular benefit.
Beyond Metabolic Research
Semaglutide research has expanded into numerous additional areas including NASH/MASH treatment, kidney disease, Alzheimer's disease, addiction research, and heart failure.
Conclusion
Semaglutide's impact on metabolic research cannot be overstated. It validated the GLP 1 pathway as a cornerstone of metabolic therapy and paved the way for next generation compounds like Tirzepatide and Retatrutide.
All products are for research purposes only. Not for human consumption.